Active Filter(s):
Details:
GMA 106 is second generation monoclonal antibody therapy rationally designed utilizing GMAX’s GPCR and M-Body technologies for the treatment of obesity/T2DM/NASH.
Lead Product(s): GMA106
Therapeutic Area: Nutrition and Weight Loss Product Name: GMA106
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2021